FDA allows Houston cancer doctor to resume drug trial

Federal regulators have lifted a partial hold on a clinical trial performed by Stanislaw

Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial - The Lancet Oncology

Ashish M. Kamat MD Anderson Cancer Center

Vaccines, Free Full-Text

Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial - The Lancet Oncology

Brian_Wice

At the Bedside: Pancreatic cancer patient 'back on track' after UTHealth Houston clinical trial therapy shrinks tumor - UTHealth Houston

A Triumph in the War Against Cancer, Science

World's First Gene Therapy Clinical Trial for Glycogen Storage Disease Approved by FDA - Connecticut Children's

The Impact of Right to Try Laws on Medical Access in the United States

GoLocalProv FDA Closes Last Option for 20-Year-Old RI Cancer Patient Facing Death

Hagop M. Kantarjian MD Anderson Cancer Center

At the Bedside: New focal therapies at UTHealth Houston make prostate cancer treatment easier on patients - UTHealth News - UTHealth Houston

Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRASG12C Mutation